McLean M J
Department of Neurology, Department of Veterans Affairs Medical Center, Nashville, Tennessee, USA.
Epilepsia. 1995;36 Suppl 2:S73-86. doi: 10.1111/j.1528-1157.1995.tb06001.x.
The amino acid antiepileptic drug (AED) gabapentin (GBP) is indicated for adjunctive use in the treatment of partial seizures with or without becoming secondarily generalized in individuals older than 12 years. GBP was about as potent as phenytoin in the maximal electroshock test, but had a different profile of efficacy than standard antiepileptics in a range of animal models. Possible mechanisms of action include biochemical effects enhancing the ratio of gamma-aminobutyric acid (GABA) to glutamate, ion-channel actions (direct or indirect), and/ or enhancement of nonsynaptic GABA release. The anticonvulsant effect appears to depend on concentration of gabapentin in neurons, presumably by the L-system amino acid transporter that has been implicated in absorption from the gut. Data from studies for U.S. Food and Drug Administration (FDA) approval suggested a direct relationship of clinical response to dose and efficacy did not plateau at the doses used. The maximally effective dose, relationship of efficacy to blood level, and maximum tolerable dose are not yet known conclusively. Lack of significant binding to plasma proteins and lack of liver metabolism contribute to the absence of known limiting drug-drug interactions, particularly with other AEDs. Excretion intact in the urine affords dose adjustment on the basis of creatinine clearance. A half-life of approximately 7 h necessitates multiple doses daily for many individuals. The medication is well tolerated, in general. Side effects tend to be mild to moderate in intensity, most frequently affect the central nervous system, and resolve with time in many individuals. GBP has been prescribed for approximately 70,000 individuals worldwide without untoward incidence of severe systemic toxicity to date. Safety data continue to accumulate. GBP has been labeled category C on the basis of effects on rodent fetuses. Experience with use in pregnant women is limited and human teratogenic effects have not been reported. Data from ongoing monotherapy trials will help to clarify the range of clinical utility of gabapentin.
氨基酸抗癫痫药物(AED)加巴喷丁(GBP)适用于12岁以上患者辅助治疗伴有或不伴有继发性全身发作的部分性癫痫发作。在最大电休克试验中,GBP的效力与苯妥英相当,但在一系列动物模型中,其疗效特征与标准抗癫痫药物不同。可能的作用机制包括增强γ-氨基丁酸(GABA)与谷氨酸比例的生化效应、离子通道作用(直接或间接)和/或增强非突触性GABA释放。抗惊厥作用似乎取决于神经元中加巴喷丁的浓度,可能是通过与肠道吸收有关的L-系统氨基酸转运体。美国食品药品监督管理局(FDA)批准研究的数据表明,临床反应与剂量呈直接关系,且在所使用的剂量下疗效未达到平台期。最大有效剂量、疗效与血药浓度的关系以及最大耐受剂量尚未完全明确。与血浆蛋白结合不显著以及缺乏肝脏代谢导致不存在已知的药物相互作用限制,特别是与其他抗癫痫药物。尿液中药物原形排泄使得可以根据肌酐清除率调整剂量。约7小时的半衰期使得许多个体需要每日多次给药。总体而言,该药物耐受性良好。副作用强度往往为轻至中度,最常影响中枢神经系统,许多个体随时间推移副作用会消失。迄今为止,全球约70000人使用GBP,未发生严重全身毒性不良反应。安全性数据仍在不断积累。基于对啮齿类动物胎儿的影响,GBP被列为C类药物。孕妇使用经验有限,尚未有人类致畸作用的报道。正在进行的单药治疗试验数据将有助于明确加巴喷丁的临床应用范围。